GlassScriptPhysician profile
Alexander Lee
NPI 1770190340
$8,369.96
in general payments reported to CMS, 2019-2025
51 companies · $22.99 in 2025
The $22.99 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $351 · 2022: $3,934 · 2023: $3,978 · 2024: $83.68 · 2025: $22.99.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,084.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,084.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,102.72 | 2021-2023 | |
| E.R. Squibb & Sons, L.L.C. | $568.94 | 2022-2023 | Opdivo, Opdualag |
| Celgene Corporation | $530.79 | 2021-2023 | Reblozyl, Opdualag, Pomalyst |
| Incyte Corporation | $511.24 | 2021-2023 | Jakafi, Pemazyre, Monjuvi |
| Janssen Biotech, INC. | $482.50 | 2021-2023 | Darzalex |
| Astellas Pharma US INC | $388.68 | 2022-2023 | Xtandi, Xospata |
| Merck Sharp & Dohme LLC | $376.19 | 2022-2023 | Keytruda, Lynparza, Welireg |
| Takeda Pharmaceuticals U.S.A., INC. | $368.97 | 2022-2023 | Alunbrig, Iclusig, Fruzaqla |
| Amgen INC. | $301.54 | 2021-2023 | Xgeva, Vectibix, Nplate |
| Eisai INC. | $298.78 | 2021-2023 | |
| Daiichi Sankyo INC. | $263.41 | 2022-2023 | Enhertu |
| Lilly USA, LLC | $249.73 | 2022-2023 | Verzenio, Jaypirca, Retevmo |
| Bayer Healthcare Pharmaceuticals INC. | $224.41 | 2022-2023 | |
| Pfizer INC. | $222.04 | 2021-2023 | |
| Karyopharm Therapeutics INC. | $196.94 | 2021-2023 | Xpovio |
Show all 51 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $174.55 | 2021-2023 | |
| Seagen INC. | $162.59 | 2022-2023 | Tivdak, Adcetris, Padcev |
| Astrazeneca Pharmaceuticals LP | $158.86 | 2022-2023 | Lynparza |
| Blueprint Medicines Corporation | $152.89 | 2022-2023 | Ayvakit |
| Abbvie INC. | $123.42 | 2023-2025 | |
| Glaxosmithkline, LLC. | $120.12 | 2022-2023 | Zejula, Jemperli, Ojjaara |
| Gilead Sciences, INC. | $112.71 | 2022-2023 | Trodelvy |
| Dendreon Pharmaceuticals LLC | $99.19 | 2021-2022 | |
| Taiho Oncology, INC. | $99.17 | 2022-2023 | |
| Exelixis INC. | $90.00 | 2023 | Cabometyx |
| Emmaus Medical, INC. | $80.09 | 2022-2023 | Endari |
| Sobi, INC | $75.45 | 2022-2023 | |
| Pharmaessentia USA Corporation | $59.69 | 2023 | Besremi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $59.45 | 2022-2023 | Gilotrif |
| Stemline Therapeutics INC. | $57.00 | 2023-2024 | Orserdu |
| Emd Serono, INC. | $55.89 | 2022-2023 | Bavencio |
| Progenics Pharmaceuticals, INC. | $52.53 | 2023 | Pylarify |
| Puma Biotechnology, INC. | $48.56 | 2022-2023 | Nerlynx |
| Immunogen, INC. | $48.55 | 2023 | Elahere |
| Agios Pharmaceuticals, INC. | $43.79 | 2023 | Pyrukynd |
| Morphosys, US INC. | $37.01 | 2022-2023 | Monjuvi |
| Tolmar Pharmaceuticals, INC. | $33.53 | 2022 | |
| Boston Scientific Corporation | $29.51 | 2024 | |
| Amneal Pharmaceuticals LLC | $27.89 | 2023 | Neulasta, Avastin, Neupogen |
| Pharmacyclics LLC, An Abbvie Company | $27.50 | 2023 | Imbruvica |
| Pharmacosmos Therapeutics INC. | $26.23 | 2023 | Monoferric |
| Catalyst Pharmaceuticals, INC. | $26.23 | 2023 | Firdapse |
| Novocure INC. | $25.69 | 2023 | Optune |
| Dova Pharmaceuticals | $24.67 | 2021 | |
| Tolmar, INC. | $24.27 | 2023 | |
| Mylan Institutional INC. | $23.61 | 2022 | |
| Global Blood Therapeutics, INC. | $22.27 | 2022 | |
| Epizyme, INC. | $21.94 | 2022 | |
| Myovant Sciences INC. | $21.30 | 2021 | |
| Jazz Pharmaceuticals INC. | $19.95 | 2022 | |
| Accord Healthcare, INC. | $16.98 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexander Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.